Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients

Annals of Pharmacotherapy

Volumn 43, Issue 11, 2009, Pages 1747-1754

  Shea, Katherine M ^a   Cheatham, S Christian ^b   Smith, David W ^c   Wack, Matthew F ^d   Sowinski, Kevin M ^e   Kays, Michael B ^e  

^a SETON FAMILY OF HOSPITALS   (United States)

^b St Francis Hospital   (United States)

^c METHODIST HOSPITAL   (United States)

^d Infectious Diseases of Indiana   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

Monte Carlo; Pharmacodynamics; Piperacillin; Prolonged infusion; Tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ABSCESS; ADULT; ARTICLE; BACTERIAL INFECTION; CITROBACTER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; ENTEROBACTER; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; PYREXIA IDIOPATHICA; SCROTUM DISORDER; SEPSIS; SERRATIA MARCESCENS; STEADY STATE; URINARY TRACT INFECTION;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN;

EID: 70449732715     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M304     Document Type: Article

References (38)

1. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin/tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Antiinfect Ther 2007;5:365-383 DOI 10.1586/14787210.5.3.365
2. Snydman DR, Jacobus NV, McDermott LA. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. Antimicrob Agents Chemother 2008;52:4492-4496 DOI 10.1128/AAC.00696-08
3. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005. DOI 10.1086/378702
4. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. DOI 10.1164/rccm.200405-644ST
5. Product information. Zosyn (piperacillin/tazobactam). Philadelphia, PA: Wyeth Pharmaceuticals, Inc., November 2007.
6. Lockhart SR, Abramson MA, Beekmann SE, et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007;45:3352-3359 DOI 10.1128/JCM.01284-07
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12. DOI 10.1086/516284
8. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy 2006;26:1320-1332 DOI 10.1592/phco.26.9.1320
9. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86. DOI 10.1086/510079
10. Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48:4718-4724 DOI 10.1128/AAC.48.12.4718-4724.2004 (Pubitemid 39577677)
11. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillintazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008;46:862-867 DOI 10.1086/528712
12. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin/tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 2007;27: 1490-1497 DOI 10.1592/phco.27.11.1490
13. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007;58:337-344 DOI 10.1016/j.diagmicrobio.2007.01.005
14. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999;43: 2559-2561 (Pubitemid 29471248)
15. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase and AmpC-producing Enterobacteriaceae from the MYSTIC program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005;53:257-264 DOI 10.1016/j.diagmicrobio.2005.10.001
16. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC program (1999-2005). Diagn Microbiol Infect Dis 2006; 56:367-372 DOI 10.1016/j.diagmicrobio.2006.07.004
17. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-668 DOI 10.1086/499819 (Pubitemid 43271379)
18. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004;26:1187-1198 DOI 10.1016/S0149-2918(04)80001-8
19. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43:1116-1123 DOI 10.1177/0091270003257225
20. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother 2009;43:220-227 Epub 3 Feb 2009. DOI 10.1345/aph.1L473
21. Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/ tazobactam, administered by prolonged infusion, in hospitalized patients (abstract 61). Presented at: International Congress on Clinical Pharmacy, American College of Clinical Pharmacy and European Society of Clinical Pharmacy, Orlando, FL, April 24-28, 2009.
22. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Comparative antimicrobial potency of meropenem tested against gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J Chemother 2005;17:459-469
23. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007;57: 207-215 DOI 10.1016/j.diagmicrobio. 2006.07.009
24. Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006). Diagn Microbiol Infect Dis 2007;59:425-432 DOI 10.1016/j.diagmicrobio.2007.05.009
25. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 2008;61:203-213 DOI 10.1016/j.diagmicrobio.2008.01.017
26. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Wayne, PA: CLSI publication M7-A7, 2007.
27. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 17th informational supplement, M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
28. Cheatham SC, Kays MB, Smith DW, Wack MF, Sowinski KM. Steadystate pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients. Pharmacotherapy 2008;28:691-698 DOI 10.1592/phco.28.6.691 (Pubitemid 351975372)
29. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22. DOI 10.1086/514622
30. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-607 DOI 10.1093/jac/dki079 (Pubitemid 40691835)
31. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumanii, Escherichia coli, and Klebsiella species collected from the United States intensive care units in 2004. Pharmacotherapy 2007;27:333-342 DOI 10.1592/phco.27.3.333
32. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006;129:1210-1218 DOI 10.1378/chest.129.5.1210
33. Loside TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-363 DOI 10.1086/510590
34. Bergan T, Williams JD. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 1982;28:153-159
35. Aronoff GR, Sloan RS, Brier ME, Luft FC. The effect of piperacillin dose on elimination kinetics in renal impairment. Eur J Clin Pharmacol 1983;24:543-547
36. Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. J Antimicrob Chemother 2001;48:259-267 (Pubitemid 32755289)
37. Klepser ME, Marangos MN, Zhu Z, Nicolau DP, Quintiliani R, Nightingale CH. Comparison of the bactericidal activities of piperacillin/ tazobactam, ticarcillin/clavulanate, and ampicillin/sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997;41:435-439
38. Occhipinti DJ, Pendland SL, Schoonover LL, Rypins EB, Danziger LH, Rodvold KA. Pharmacokinetics and pharmacodynamics of two multipledose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 1997;41:2511-2517